Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

被引：8
|
作者：
Slade, Michael [1 ]
Martin, Thomas G. [2 ]
Nathwani, Nitya [3 ]
Fiala, Mark A. [1 ]
Rettig, Michael P. [1 ]
Gao, Feng [1 ]
Deol, Abhinav [4 ]
Buadi, Francis K. [5 ]
Kaufman, Jonathan L. [6 ]
Hofmeister, Craig C. [6 ]
Gregory, Tara K. [7 ]
Berdeja, Jesus [8 ]
Chari, Ajai [9 ]
Rosko, Ashley [10 ]
Vij, Ravi [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO 63130 USA
[2] Univ Calif San Francisco, San Francisco, CA USA
[3] City Hope Comprehens Canc Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Duarte, CA USA
[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[5] Mayo Clin, Rochester, MN USA
[6] Emory Univ, Atlanta, GA USA
[7] Sarah Cannon Res Inst, Denver, CO USA
[8] Sarah Cannon Res Inst, Nashville, TN USA
[9] Icahn Sch Med Mt Sinai, New York, NY USA
[10] Ohio State Univ, Columbus, OH 43210 USA
来源：
LEUKEMIA | 2022年 / 36卷 / 12期
基金：
美国国家卫生研究院;
关键词：
STEM-CELL TRANSPLANTATION; ORAL IXAZOMIB; BORTEZOMIB;
D O I：
10.1038/s41375-022-01691-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2917 / 2921
页数：5
相关论文
共 50 条
  • [41] Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China
    Zhe Zhuang
    Ying Tian
    Hong Yu
    Lei Shi
    Tian, Wei-wei
    Liu, Qinhua
    Zou, Dongmei
    Fei Dong
    Ma, Yanping
    Ru Feng
    Liu, Shuangjiao
    Hui Liu
    Jing, Hongmei
    Sun, Wanling
    Ma, Liangming
    Li Bao
    Rong Fu
    Yin Wu
    Chen Wenming
    Zhuang, Junling
    [J]. BLOOD, 2022, 140 : 12637 - 12639
  • [42] IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOR RELAPSED MULTIPLE MYELOMA: AN EARLY SINGLE CENTER EXPERIENCE IN RUSSIA
    Luchinin, A.
    Semochkin, S.
    Minaeva, N.
    Samarina, S.
    [J]. HAEMATOLOGICA, 2018, 103 : 40 - 40
  • [43] Ixazomib, lenalidomide and dexamethasone: a winning first all-oral triplet for multiple myeloma
    Paillassa, Jerome
    [J]. HEMATOLOGIE, 2016, 22 (03): : 181 - +
  • [44] FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
    Pulte, Elizabeth Dianne
    Dmytrijuk, Andrew
    Nie, Lei
    Goldberg, Kirsten B.
    McKee, Amy E.
    Farrell, Ann T.
    Pazdur, Richard
    [J]. ONCOLOGIST, 2018, 23 (06): : 734 - 739
  • [45] Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03
    Perrot, Aurore
    Roussel, Murielle
    Lauwers-Cances, Valerie
    Hulin, Cyrille
    Leleu, Xavier
    Touzeau, Cyrille
    Facon, Thierry
    Mariette, Clara
    Schiano, Jean-Marc
    Gay, Julie
    Montes, Lydia
    Ranta, Dana
    Huguet, Amandine
    Wuilleme, Soraya
    Dejoie, Thomas
    Devlamynck, Laure
    Corre, Jill
    Avet-Loiseau, Herve
    Moreau, Philippe
    Attal, Michel
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2024,
  • [46] Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
    Kumar, Shaji
    Moreau, Philippe
    Hari, Parameswaran
    Mateos, Maria-Victoria
    Ludwig, Heinz
    Shustik, Chaim
    Masszi, Tamas
    Spencer, Andrew
    Hajek, Roman
    Romeril, Kenneth
    Avivi, Irit
    Liberati, Anna M.
    Minnema, Monique C.
    Einsele, Hermann
    Lonial, Sagar
    Berg, Deborah
    Lin, Jianchang
    Gupta, Neeraj
    Esseltine, Dixie-Lee
    Richardson, Paul G.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (04) : 571 - 582
  • [47] A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients
    Silvennoinen, Raija
    Waage, Anders
    Peceliunas, Valdas
    Schjesvold, Fredrik
    Anttila, Pekka
    Uttervall, Katarina
    Saily, Marjaana
    Putkonen, Mervi
    Carlson, Kristina
    Haukas, Einar
    Sankelo, Marja
    Partanen, Anu
    Szatkowski, Damian
    Hansson, Markus
    Marttila, Anu
    Svensson, Ronald
    Axelsson, Per
    Lauri, Birgitta
    Mikkola, Maija
    Karlsson, Conny
    Abelsson, Johanna
    Ahlstrand, Erik
    Sikio, Anu
    Nahi, Hareth
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S157 - S157
  • [48] Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma
    Ohashi, Yasukata
    Yatabe, Megumi
    Niijima, Daisuke
    Tani, Kentaro
    Ogawa, Chiaki
    Yachi, Yutaka
    Kagoo, Toshiya
    Boku, Saigen
    Ueno, Hironori
    Yano, Takahiro
    Higai, Koji
    Yokoyama, Akihiro
    [J]. IN VIVO, 2020, 34 (05): : 2821 - 2828
  • [49] Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-Transplant Myeloma Patients
    Patel, Krina K.
    Shah, Jatin J.
    Feng, Lei
    Lee, Hans C.
    Manasanch, Elisabet M.
    Olsem, Jasper
    Morphey, Ashley
    Huo, Xiao Jiao
    Thomas, Sheeba K.
    Bashir, Qaiser
    Qazilbash, Muzaffar H.
    Weber, Donna M.
    Orlowski, Robert Z.
    [J]. BLOOD, 2021, 138
  • [50] NET IMPACT ANALYSIS OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA FOR QUEBEC
    Pettigrew, M.
    Garces, K.
    [J]. VALUE IN HEALTH, 2018, 21 : S29 - S29
12345